Relevant bibliographies by topics / Gamma globulins Therapeutic use

Academic literature on the topic 'Gamma globulins Therapeutic use'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Gamma globulins Therapeutic use.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Gamma globulins Therapeutic use"

1

Abukova, R. A. "Hypogammaglobulinemia and therapeutic use of gamma globulin." Kazan medical journal 43, no. 3 (October 29, 2021): 82–85. http://dx.doi.org/10.17816/kazmj84095.

Full text
Abstract:
In the Soviet Union, gammaglobulin was first obtained in 1946 by Kholchev and Kolesnikova from the blood serum of donors. At first, it was used to prevent measles, and then, as the content of various antibodies in it was studied, it began to be used for poliomyelitis (Leitman, Strakhova, Denisenko, Bogdanov), Botkin's disease (Ananiev, Grachev, Fabrikantov), ​​whooping cough (Khropetskaya), scarlet fever ( Kaushanskaya, Zhagullo, Mauerman). Gammaglobulins were also obtained from the blood serum of animals, which were successfully used for rabies (Selimov, Durasova, Kovalevskaya. Kobrinsky, Chun-syun), plague (Semenova, Ponomareva), smallpox (Mirosennikova). Gammaglobulin in industrial conditions is prepared from the placental serum of healthy women in labor.
APA, Harvard, Vancouver, ISO, and other styles
2

Lazarenko, A. A., L. M. Alimbarova, E. Yu Mordvintseva, and I. F. Barinsky. "Development of the suppository form of human immunoglobulin preparation with high titers of antibodies to herpes simplex virus types 1 and 2 for the treatment of chronic forms of herpetic disease." Problems of Virology, Russian journal 62, no. 1 (February 20, 2017): 36–41. http://dx.doi.org/10.18821/0507-4088-2017-62-1-36-41.

Full text
Abstract:
In spite of the vast arsenal of therapeutic agents, therapy of herpes virus infection (HVI) is very difficult, particularly in pregnant women, newborns and children in the first years of life, as well as in patients with immune deficiency. In this regard, possibility of using immunoglobulins for the treatment of HVI is currently attracting the attention of doctors. The aim of this work was to develop a suppository form of the drug containing donor immunoglobulins with high levels of neutralizing antibodies to herpes simplex virus types 1 and 2 for the treatment of chronic forms of herpetic disease. The study included the following steps: 1) selection of gamma-globulins with high antibody titer for HSV-1 and HSV-2 ELISA test; 2) determination of the level of neutralizing antibodies in the selected series of gamma-globulins in tests in tissue cultures and animals; 3) lyophilization of immunoglobulins; 4) development of the suppository form of the preparation containing gamma-globulin donors with high levels of neutralizing antibodies to HSV-1 and HSV-2; 5) study of the safety of the activity of neutralizing antibodies to HSV-1 and HSV-2 in the suppository form of the drug with hyaluronic acid used as immunomodulator. As the result of this work, immunoglobulin preparation in the suppository form was developed. The developed preparation meets the requirements for safety and efficacy. It is not toxic or pyrogenic. The problems of clinical use of this drug as a method of HVI therapy are discussed.
APA, Harvard, Vancouver, ISO, and other styles
3

Ramesh, Sujatha, and Stanley A. Schwartz. "Therapeutic Uses of Intravenous Immunoglobulin (IVIG) in Children." Pediatrics In Review 16, no. 11 (November 1, 1995): 403–10. http://dx.doi.org/10.1542/pir.16.11.403.

Full text
Abstract:
Introduction HISTORY Immunologists have been aware of the existence of protective humoral substances in the serum of patients after an infectious episode for a long time. Serum harvested from large animals after their immunization with specific pathogens was injected into humans for the prophylaxis and treatment of serious infections. The concept of immunoglobulin (also called gamma globulin) therapy originated from these early experiments. Subsequently, Paul Ehrlich produced antitoxin to diphtheria in 1897. To avoid complications such as serum sickness with the use of animal serums, attempts were made to concentrate the antibody-containing fractions of human serum. In 1936, placental immunoglobulin samples were used for prophylaxis of measles. In 1952, Bruton recognized that an 8-year-old child who had serious recurrent infections despite conventional therapy was incapable of making significant quantities of immunoglobulin. This was the first time primary immunodeficiency was diagnosed and treated successfully with intramuscular immunoglobulin. Since then, and until 1981, intramuscular gamma globulin or, alternatively, fresh frozen plasma has been the mainstay of treatment of hypogammaglobulinemia and other primary immune deficiencies. In 1981, intravenous immunoglobulin (IVIG) became available commercially in the United States. The advantages of IVIG over intramuscular gamma globulin are: 1) administration is relatively painless; 2) higher doses can be given, resulting in rapid achievement of therapeutic levels, because volume is not a limitation: 3) its absorption is good: 4) it does not undergo local degradation during infusion; and 5) it does not aggregate and activate complement.
APA, Harvard, Vancouver, ISO, and other styles
4

Shabaldin, A. V., N. S. Deeva, А. S. Sukhikh, G. V. Vavin, and P. M. Kryukov. "Altered expression of cell membrane HLA-G molecules in mothers of children with inborn heart defects upon exposure to plasma gamma-globulin from multiparous women." Russian Journal of Immunology 24, no. 3 (July 15, 2021): 373–76. http://dx.doi.org/10.46235/1028-7221-987-aeo.

Full text
Abstract:
High incidence of newborns with inborn heart defects (HD) and sufficient contribution of this disorder into perinatal, infant and pediatric mortality, as well as disability levels, even after radical surgical treatment determine significance of search for novel methods of prediction and prevention of appropriate HD risks at the stage of pregnancy planning. HLA-G is among key molecules participating in immune interactions between maternal microenvironment and embryos. Maximal antibody titers for HLA antigens is detected in multiparous women. However, the question remains open, which HLA molecules participate in blockage of immune inflammation in the mother-embryo system: either by maternal antibodies, or by donor immune globulins. Hence, the aim of our study was to obtain enriched γ-globulin preparation from blood of multiparous women and evaluation of its activity towards female HLA-G molecules. The γ-globulin fraction (GGF) was obtained from blood plasma of muliparous women by means of affine chromatography using DEAE Affi-Gel Blue system (BioRad, USA). We have formed 2 groups: a control group (14 healthy males), and experimental group of 14 women who gave birth to the children with inborn heart defects.The changes of HLA-G expression on lymphocytes exposed to GGF were evaluated according to a flow cytometry protocol with calculation of percentage values using appropriate quotients. Evaluation of functional activity exerted by the GGF concentrate in control group showed inhibition of HLA-G expression on CD3+ and CD--lymphocytes against effects of autologous serum. GGF effects in experimental group upon HLA-G expression were differently directed, e.g., GGF sufficiently inhibited membrane HLA-G expression on the CD3-negative lymphocytes, compared to control group. Meanwhile, GGF showed stimulatory effect upon CD3+-lymphocytes, or it did not show any inhibitory action. The preparation obtained may serve as prototype for intravenous infusion. Moreover, in future one may use such immunoglobulin preparations, both for immune prophylaxis of non-syndromal sporadic HDs at the pregragravidary stage, as well as at early terms of pregnancy. The therapeutic effect will achieved due to blockage of embryoblast HLA molecules available to recognition.
APA, Harvard, Vancouver, ISO, and other styles
5

Byakova and Pilip. "THE ANTIOXIDANT IN THE COMPOSITIONOF ANTIPARASITIC PASTE FOR HORSES." THEORY AND PRACTICE OF PARASITIC DISEASE CONTROL, no. 20 (May 14, 2019): 161–66. http://dx.doi.org/10.31016/978-5-9902340-8-6.2019.20.161-166.

Full text
Abstract:
The long-running parasitic process adversely affects the viability of the antioxidant defense system, which is reflected in an increase in the onset of the maximum signal reduction and a decrease in the AOA. For the treatment of equine helminth infections, drugs are needed that combine high anthelmintic efficacy with a simultaneous immunostimulating effect. The use of antioxidants in the composition of antiparasitic drugs increases the effectiveness of deworming. The use of the antiparasitic drug alezan containing ivermectin, praziquantel and antioxidant santohin in helminthiases of horses once at the rate of 1 g of paste per 100 kg of animal weight in a therapeutic dose ensured the complete elimination of worms from the host's body by the 10th day of research. The drug is used for therapeutic and prophylactic purposes. Significant changes in the content of total protein, alpha- and gamma-globulins, AlAt and AsAt by the 28th day of research indicate that there is no negative effect of deworming. Information was obtained on the positive effect of the antiparasitic paste with antioxidant on the light sum (S) and maximum flare (Imax), which is characterized by a decrease in the level of free radical lipid oxidation with a decrease in the light sum of radicals by 14.6% and an increase in the antioxidant activity of horse serum by 26.5% on the 7th day. By the 14th day, the radical sum of radicals decreased by 16.9%, the maximum luminescence intensity – by 34.3%, and on the 28th day the light sum index was 26.73, which corresponded to the standard data. With chronic parasitic invasion, a low AOA was observed.
APA, Harvard, Vancouver, ISO, and other styles
6

Cowchock, S. "Prevention of Fetal Death in the Antiphospholipid Antibody Syndrome." Lupus 5, no. 5 (October 1996): 467–72. http://dx.doi.org/10.1177/096120339600500528.

Full text
Abstract:
The first treatment of pregnant women with antiphospholipid antibody syndrome (APLS) employed high doses of corticosteroids, plus low dose aspirin, with the goal of suppressing production of the autoantibody. Corticosteroids (usually prednisone), even when much lower doses are used, and even when tapered after midpregnancy, have been associated with significant maternal and obstetric risks and side effects: the most important are osteomalacia and preterm delivery (often precipitated by premature rupture of the membranes). Since the publication of a randomized trial demonstrating equivalent live birth rates of about 75% whether heparin or prednisone was used for treatment (plus low dose aspirin), the use of adjusted doses of heparin, together with low dose aspirin, has replaced prednisone for treatment of pregnant women; although prednisone may still be needed to treat manifestations of associated autoimmune disorders. A recent randomized trial has shown that the addition of heparin to aspirin is probably superior to treatment with aspirin alone. To achieve prophylactic levels of plasma heparin equivalent to those measured in patients who are not pregnant and are treated with the usual dose of standard heparin of 5000 IU every 12 h, the heparin dose required for treatment of pregnant women is usually higher. For that reason, heparin doses should be adjusted using the nadir APTT, or better plasma heparin measured by a factor Xa inhibition assay at the 2 h post-injection peak. Although low molecular weight heparin has been shown to be useful in prevention of fetal resorption in a mouse model, and appears to be equally safe for treatment of pregnant women, we still have no published data to show therapeutic equivalency, with respect to treatment of APLS-complicated pregnancy, to standard heparin preparations, and none that demonstrate any lower risk for the complication of most concern when heparin is given to pregnant women—osteopenia. Similarly, intravenous infusion of gamma globulins (IVG) appears on the basis of case reports to be effective additional treatment in cases where standard therapy has failed. Gamma globulin preparations contain anti-idiotypic antibodies that have been shown to bind to patient antiphospholipid antibodies. The place for the addition of IVG to standard therapy has not been defined, but clinically significant and corticosteroid-resistant thrombocytopenia complicating antiphospholipid antibody syndrome might be one indication for primary treatment with IVG ± low dose aspirin. Overall, live birth rates in most treatment studies are in the range of 70–80%. The reported birth rate information, however, cannot be compared between studies. None of the studies reported have used tools such as logistic regression analysis to allow for such significant predictors of live birth as the number of prior miscarriages, maternal age, medical history, or a history of fetal death (loss of a viable and chromosomally normal fetus after the 10th gestational week).
APA, Harvard, Vancouver, ISO, and other styles
7

Metlin, A. E., A. D. Botvinkin, A. L. Elakov, and K. N. Gruzdev. "СASES OF HUMAN CONVALESCENCE FROM RABIES AND LIFETIME DIAGNOSTICS OF LYSSAVIRUS ENCEPHALITIS." Problems of Virology, Russian journal 64, no. 1 (February 20, 2019): 42–48. http://dx.doi.org/10.18821/0507-4088-2019-64-1-42-48.

Full text
Abstract:
Notwithstanding the availability of effective vaccines, 40 - 60 thousand rabies cases in humans are reported every year. Almost always the disease is fatal because therapeutic treatment of lyssavirus encephalitis has not been developed. Since 1970 the number of reports on rare cases of convalescence including those using experimental treatment protocols has been gradually increasing 20 cases of convalescence, “partial” convalescence or long-term survival of humans (1970-2015) were selected as they were complaint with laboratory criteria of active lyssavirus infection. Children and teenagers were predominant in the analyzed group (85%). The cases were irregularly spread between the continents: Asia - 6 cases, North America - 6 cases, Africa - 2 cases and Europe - 1 case. India and the USA were on the top of the list of countries by the number of described cases. More than 60% humans were infected from dogs, three cases got infection from bats and 2 cases were allegedly associated with an unknown lyssavirus and an unidentified infection source. 70% cases were vaccinated and 10% cases were treated with gamma globulin before the disease onset. Serological tests for detection of antibodies to lyssaviruses in cerebrospinal fluid of infected humans were typically used for diagnostic laboratory verification. Less than 30% IFA and PCR positives were obtained. Lyssaviruses were never detected. Only 4 convalescent patients were treated using experimental protocols. 80% cases demonstrated severe neurological consequences, four (may be more) patients died afterwards within the period from two months to four years. Different perspectives on prospects of Milwaukee protocol use and other therapeutic techniques are given.
APA, Harvard, Vancouver, ISO, and other styles
8

Latov, Norman, Vinay Chaudhry, Carol Lee Koski, Robert P. Lisak, Brian R. Apatoff, Angelika F. Hahn, and James F. Howard Jr. "Use of intravenous gamma globulins in neuroimmunologic diseases☆☆☆." Journal of Allergy and Clinical Immunology 108, no. 4 (October 2001): S126—S132. http://dx.doi.org/10.1067/mai.2001.118300.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Marquez, Audrey de Souza, Adriana Pardini Vicentini Moreira, Paula Cesar Leonello, Fernanda Akemi Nakanishi, and Eiko Nakagawa Itano. "Serum proteins and fractions, HDL-cholesterol and total IgG and IgE levels in cases of acute and chronic paracoccidioidomycosis." Revista da Sociedade Brasileira de Medicina Tropical 42, no. 3 (June 2009): 245–49. http://dx.doi.org/10.1590/s0037-86822009000300002.

Full text
Abstract:
This study evaluated serum protein fractions, HDL-cholesterol, total immunoglobulin G and total immunoglobulin E levels in patients with acute and chronic paracoccidioidomycosis, by means of electrophoresis, enzymatic reaction and immunoenzymatic assay. The results demonstrated elevated levels of total immunoglobulin G, total immunoglobulin E, alpha-2 and gamma-globulins, which were more evident in acute than in chronic PCM, but no increase in HDL-cholesterol levels. There was a correlation between the levels of total immunoglobulin E and gamma-globulins and the alpha-2 and beta-globulin fractions in the acute form and between beta and gamma-globulins in both the acute and the chronic form. In conclusion, changes in total immunoglobulin G and immunoglobulin E levels and in the electrophoretic profile may be important markers for the prognosis and therapeutic follow-up of PCM cases, especially because protein electrophoresis is a simple laboratory test that can be applied when specific PCM serological tests are not available. In addition, levels of the gamma-globulin fraction greater than 2.0g/dl may suggest that the patient is developing a more severe form of PCM.
APA, Harvard, Vancouver, ISO, and other styles
10

Ferreira, Hugo Henrique de Freitas, Alessandra Suelen Jardim Silva, Lenilton Silva DA Silva Júnior, Gustavo Henrique de Medeiros Oliveira, Maria das Graças Pereira Araujo, Victor lima Soares, Frank Bahia, et al. "Multiple Myeloma Course with Renal Insufficiency in Young Patient: Case Report." Blood 136, Supplement 1 (November 5, 2020): 26. http://dx.doi.org/10.1182/blood-2020-143302.

Full text
Abstract:
Introduction: Multiple myeloma (MM) is a malignant neoplasm characterized by the clonal proliferation of abnormal plasma cells in the bone marrow (OM). The average age of patients diagnosed with MM is approximately 70 years, being relatively uncommon in younger individuals. Objective: To report a case of a young patient with multiple myeloma. Case Description: A 42-year-old male patient presented with continuous and progressive low back pain for 3 months, associated with adynamia, weight loss (10 kg), episodes of constipation and bleeding in the oral cavity in this period. Examinations at the first appointment revealed moderate anemia (Hb 7.4 g / dL), leukocytosis, thrombocytopenia, hypercalcemia, and altered renal function (Cr 5.9 and Ur 178), chest tomography indicating vertebral fracture in T6, T11, L2 and L4. Referred for specialized follow-up, he performed electrophoresis of serum proteins with the presence of a monoclonal peak in the gamma globulin fraction. The immunofixation test confirmed monoclonality for IgA isotype and Kappa light chain (IgA / Kappa). The myelogram showed plasmacytosis of more than 50% of mononuclear cells in the bone marrow. He developed renal failure (with dosage of creatinine of 10.1 mg/ dL. and urea of 208 mg/dL) and hypercalcemia requiring dialysis therapy on the third day of hospitalization, having undergone chemotherapy with Bortezomib, cyclophosphamide and dexamethasone. During this period, infection by the multisensitive S. aureus in catheter occurred and, despite being treated with specific antibiotic therapy, it evolved with clinical worsening and hemodynamic instability and was referred to the Intensive Care Unit, going to death after 2 days. Conclusion: Young patients with MM may study with more aggressive characteristics. Despite the use of new therapeutic agents, more effective treatment strategies need to be studied more for patients in this age group. Disclosures No relevant conflicts of interest to declare.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Gamma globulins Therapeutic use"

1

Smeets, Julien. "Prompt gamma imaging with a slit camera for real time range control in particle therapy." Doctoral thesis, Universite Libre de Bruxelles, 2012. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/209624.

Full text
Abstract:
In a growing number of cutting edge centres around the world, radiotherapy treatments delivered by beams of protons and carbon ions offer the opportunity to target tumours with unprecedented conformality. But a sharper dose distribution increases the need for efficient quality control. Treatments are still affected by uncertainties on the penetration depth of the beam within the patient, requiring medical physicists to add safety margins. To reduce these margins and deliver safer treatments, different projects investigate real time range control by imaging prompt gammas emitted along the proton or carbon ion tracks in the patient.

This thesis reports on the feasibility, development and test of a new type of prompt gamma camera for proton therapy. This concept uses a knife-edge slit collimator to obtain a 1-dimensional projection of the beam path on a gamma camera. It was optimized, using the Monte Carlo code MCNPX version 2.5.0, to select high energy photons correlated with the beam range and detect them with both high counting statistics and sufficient spatial resolution for use in clinical routine. To validate the Monte Carlo model, spectrometry measurements of secondary particles emitted by a PMMA target during proton irradiation at 160 MeV were realised. An excellent agreement with the simulations was observed when using subtraction methods to isolate the gammas in direct incidence. A first prototype slit camera using the HiCam gamma detector was consequently prepared and tested successfully at 100 and 160 MeV beam energies. If we neglect electronic dead times and rejection of detected events, the current solution with its collimator at 15 cm from beam axis can achieve a 1-2 mm standard deviation on range estimation in a homogeneous PMMA target for numbers of protons that correspond to doses in water at Bragg peak as low as 15 cGy at 100 MeV and 25 cGy at 160 MeV assuming pencil beams with a Gaussian profile of 5 mm sigma at target entrance.

This thesis also investigates the applicability of the slit camera for carbon ion therapy. On the basis of Monte Carlo simulations with the code MCNPX version 2.7.E, this type of camera appears not to be able to identify the beam range with the required sensitivity. The feasibility of prompt gamma imaging itself seems questionable at high beam energies given the weak correlation of secondaries leaving the patient.

This work consequently concludes to the relevance of the slit camera approach for real time range monitoring in proton therapy, but not in carbon ion therapy.
Doctorat en Sciences de l'ingénieur
info:eu-repo/semantics/nonPublished

APA, Harvard, Vancouver, ISO, and other styles
2

"Biological and pharmacological studies of a lead compound that can activate the human gamma globin expression." Thesis, 2010. http://library.cuhk.edu.hk/record=b6075077.

Full text
Abstract:
Different cucurbitacin derivatives have been compared for the gamma globin induction potential. Cucurbitacin D turned out to be the most potential inducer among the derivatives had been tested. Later I had screened more herbs for the gamma globin induction activities. One of the herbs showed a higher activity than Fructus Trichosanthis, which could be the potential candidate to isolate more potent inducer. In the toxicity study, cucurbitacin D only have a mild toxic effect on the normal cell lines and transgenic mice. Finally, the efficacy of cucurbitacin D was tested on a sickle cell anemia mouse model and demonstrated a significant induction of fetal haemoglobin production. Cucurbitacin D may be a potential drug candidate for treating beta globinopathies.
Thalassemia is a global disease. It was report in 2001 that there were 270 million people who carried the severe disease. Most of the cases were found in Africa and south-east Asia. China has a high incidence rate of 0.66% in 2001. In the past, the treatments of the disease were blood transfusion and bone marrow transplantation. However, many defects in such kinds of treatments were reported. The balance of relieving the syndrome of the disease and the adverse effects of the drugs was the consideration to the physician. The drug, hydroxyurea, can activate the gamma globin gene and produce hemoglobin F to replace the beta globin as an oxygen transporter is considered as an better treatment to ameliorate the syndrome. Safety and effectiveness in the long-term treatment using hydroxyurea are questionable. Cucurbatacin D purified from a Chinese herb demonstrates 2000 folds more potent than hydroxyurea. It can activate the gamma globin gene and produce hemoglobin F shown in ELISA and confocal microscopy. The fundamental work for drug development is carrying out through this project. In this project the biological property and toxicity were studied.
Liu, Shuk Ming.
Adviser: M.C. Tung.
Source: Dissertation Abstracts International, Volume: 73-02, Section: B, page: .
Thesis (Ph.D.)--Chinese University of Hong Kong, 2010.
Includes bibliographical references (leaves 245-270).
Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web.
Electronic reproduction. [Ann Arbor, MI] : ProQuest Information and Learning, [201-] System requirements: Adobe Acrobat Reader. Available via World Wide Web.
Abstract also in Chinese.
APA, Harvard, Vancouver, ISO, and other styles
3

"Molecular analyses of the mechanisms of cucurbitacin D (CuD)-induced human gamma-globin gene activation in K562 cells." Thesis, 2011. http://library.cuhk.edu.hk/record=b6075155.

Full text
Abstract:
Liu, Kan.
"November, 2010"--Abstract.
Thesis (Ph.D.)--Chinese University of Hong Kong, 2011.
Includes bibliographical references (leaves 116-129).
Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web.
Abstract also in Chinese.
APA, Harvard, Vancouver, ISO, and other styles
4

Khumalo, Nozipho Lindiwe. "Optimisation of the lion (Panthera leo) specific interferon gamma assay for detection of tuberculosis in lions in South Africa." Diss., 2017. http://hdl.handle.net/10500/27011.

Full text
Abstract:
Mycobacterium bovis is the causative agent of bovine tuberculosis (BTB) which has a diverse host range. The maintenance host of BTB in South Africa is the African buffalo (Syncerus caffer). It is believed that lions get infected by feeding on infected buffalo or through wounds. The spread of the disease amongst lions has raised concern regarding the future of the animals and the impact on tourism in the country. Diagnoses of tuberculosis in free ranging wildlife is often dependent on post-mortem samples due to logistical challenges, the use of the lion specific interferon gamma release assay as an antemortem test offers a simpler methodology to testing live animals. The aim was to optimise an already developed assay by Maas et al.,2012 and to harmonise it with the Rhinoceros specific interferon gamma assay developed by Morar-Leather et al 2007. Optimisation of the interferon gamma specific ELISA included: determination of optimal concentrations for the capture and detection monoclonal antibodies; optimal concentrations for the conjugate and evaluation of alternative blocking agents. Different mitogens and incubation times were evaluated for the stimulation of whole blood as positive control in the assay. The optimum concentration for coating the plates with the capture monoclonal antibody was 2 g/ml. An optimum dilution of 1:5000 was selected for both the biotinylated detection monoclonal antibody and the streptavidin horseradish peroxidase conjugate. The assay was optimised using recombinant lion interferon gamma and the lower detection limit was calculated to be 109 pg/ml. Phosphate buffered saline with 1% bovine serum albumin was found to be Chapter 1 © University of South Africa iii a suitable blocking agent. Native interferon gamma was detected in whole blood samples from 5 lions and a 24 hour incubation time with PMA and ionomycin was selected as the optimal mitogen positive control. This assay system demonstrated good potential as an ante mortem test for the diagnosis of tuberculosis in lions. In conclusion, the assay can detect IFN- from supernatants harvested from whole blood cultures stimulated with specific antigens and mitogens
Agriculture and  Animal Health
M. Sc. (Agriculture)
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Gamma globulins Therapeutic use"

1

International Symposium on IVIG (4th 1996 Interlaken, Switzerland). Advances in intravenous immunoglobulin research and therapy: Proceedings from Interlaken's Fourth International Symposium on IVIG, 11-13 June, 1996. New York: Parthenon Pub. Group, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Weaver, James T. Calibration of gamma-ray-emitting brachytherapy sources. Gaithersburg, MD: U.S. Dept. of Commerce, National Bureau of Standards, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dr, Huang Yung-Sheng, Mills David E, and International Symposium of GLA (1st : 1995 : San Antonio, Tex.), eds. [Gamma]-linolenic acid: Metabolism and its roles in nutrition and medicine. Champaign, Ill: AOCS Press, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

United States. Congress. House. A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to immune globulins. [Washington, D.C.?]: [United States Government Printing Office], 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Senate, United States Congress. A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins. Washington, D.C: U.S. G.P.O., 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lucchini, Alfio. ItaliaAlcol: Studi e ricerche in alcologia. Milano, Italy: FrancoAngeli, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Takao, Kumazawa, Kruger Lawrence, and Mizumura Kazue, eds. The polymodal receptor: A gateway to pathological pain. Amsterdam: Elsevier, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

J, Garner Ronnie, and Sacher Ronald A, eds. Intravenous gammaglobulin therapy. Arlington, Va: American Association of Blood Banks, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Intravenous Immunoglobulin: Research and Therapy. Informa Healthcare, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ballow, Mark. IVIG Therapy Today. Humana Press, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Gamma globulins Therapeutic use"

1

Metzger, Hermann P., and Michael Schywalsky. "Observation of Microcirculatory Disorders of the Hemorrhagic Rat Liver by Use of Fluorescence-Stained Gamma Globulins." In Microcirculation in Circulatory Disorders, 235–44. Tokyo: Springer Japan, 1988. http://dx.doi.org/10.1007/978-4-431-68078-9_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Winter, Jerrold. "Methylenedioxymethamphetamine (MDMA): a.k.a. Ecstasy." In Our Love Affair with Drugs. Oxford University Press, 2020. http://dx.doi.org/10.1093/oso/9780190051464.003.0012.

Full text
Abstract:
As these words are written, the chemical we will call MDMA is a Schedule I drug. This means that MDMA (a) has no currently accepted medical use, (b) no currently accepted safety even under medical supervision, and (c) has a high potential for abuse. On the other hand, there are those who see great therapeutic potential in MDMA, and the Food and Drug Administration (FDA) has designated MDMA- assisted psychotherapy as a breakthrough therapy. We can foresee the day when it will be available by prescription. There is no doubt as to the chemical identity of MDMA, and much is known of its pharmacological effects in humans and in animals. The recreational drug commonly known as Ecstasy is more complicated. As is true for any illegal drug used by millions of people, demand for the drug has been met by persons not noted for their high ethical or manufacturing standards. Simply stated, short of chemical analysis, one can never be sure what street-bought Ecstasy is. For example, investigators at Vanderbilt University determined the contents of 1,214 tablets sold as Ecstasy. Only 39% contained only MDMA, while fully 46% were “substances other than MDMA.” Mixtures of MDMA and other drugs comprised the remaining 15%. On the other hand, sometimes in some places over the past several decades, nearly pure MDMA has been available on the illicit market. Nonetheless, a buyer of Ecstasy may ingest, rather than MDMA, drugs such as ketamine, gamma-hydroxybutyrate (GHB), cathinone, ephedrine, caffeine, or any one of the so-called designer drugs, many of which are amphetamine derivatives. A consequence of this pharmacological chaos is that many of the hazards associated with the use of Ecstasy have been uncritically attributed to MDMA. This fact has been a boon for those who would continue the Schedule I status of MDMA and a bane for those who would explore its therapeutic potential. However, in contrast with recreational use where purity of the drug is uncertain, MDMA in clinical trials is FDA approved and of known composition.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Gamma globulins Therapeutic use"

1

Kabuki, S., K. Ueno, S. Kurosawa, S. Iwaki, H. Kubo, K. Miuchi, Y. Fujii, et al. "Study on the use of electron-tracking Compton gamma-ray camera to monitor the therapeutic proton dose distribution in real time." In 2009 IEEE Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC 2009). IEEE, 2009. http://dx.doi.org/10.1109/nssmic.2009.5402130.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sultan, Y. "PROGRESSION OF HIV INFECTION IN THE POPULATION OF FRENCH HEMOPHILIACS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644682.

Full text
Abstract:
A national inquiry including 28 hemophilia centers was carried out in France in order to appreciate the epidemiology of HIV infection among hemophilic patients. Information about 1781 patients was obtained with an overall prevalence of 50% seropositive patients. This percentage of HIV seropositivity was unchanged in comparison with 1985 confirming that no seroconversion was observed since the use of heat treated products for bleeding episodes. It is to be noted that there is an important progression in the number of AIDS which increased from 16 hemophiliacs last year to 23 this year with a total of 11 deaths against 7 last year related to this affection. In the' remaining hemophilic population, twenty per cent of HIV positive patients have developed an ARC. For the biological abnormalities related to immune deficiency, it was found that patients with lymphopenia less than 1000 lymphocytes had not progressed and represent 23 patients. Patients with thrombocytopenia less than 150,000 platelets had increased from 29 to 62. Patients with a number of T4 lymphocytes subset less than 400 ha increased from 54 to 110. 22% of HIV positive hemophiliacs had a T4/T8 ratio less than 1 in 1986 in comparison with 11% in 1985.17.5% of HIV positive population showed an elevated level of gamma-globulins above 20 g/liter of plasma against 12.5% last year. The conclusion of the present study is that HIV infectionhas progressed in severity from 1985 to 1986 in the population of multitransfused HIV positive French hemophiliacs.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Gamma globulins Therapeutic use' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography